Category: Press Releases

Press Releases

BIONXT ACQUIRES COMMERCIAL COATING AND CUTTING EQUIPMENT TO BUILD OUT EUROPEAN COMMERCIAL MANUFACTURING CAPACITY

Apr 17, 2023

VANCOUVER, BC – April 17, 2023 ‐ BioNxt Solutions Inc. (“BioNxt” or the “Company”) (CSE: BNXT / OTC: BNXTF / FSE: BXT) is pleased to...

Continue Reading

Drug Delivery, Press Releases

BIONXT SOLUTIONS ACQUIRES NOVEL PRECISION DRUG COATING AND DELIVERY TECHNOLOGY

Mar 7, 2023

VANCOUVER, BC – March 07, 2023 ‐ BioNxt Solutions Inc. (“BioNxt” or the “Company”) (CSE: BNXT / OTC: BNXTF / FSE: BXT) is pleased to...

Continue Reading

Drug Delivery, Press Releases

BIONXT SIGNS CLINICAL STUDY AGREEMENT AND COMMENCES MANUFACTURE OF CLINICAL SAMPLES FOR STUDY OF TRANSDERMAL ROTIGOTINE PATCH FOR PARKINSON’S DISEASE

Mar 1, 2023

VANCOUVER, BC – March 1, 2023 ‐ BioNxt Solutions Inc. (“BioNxt” or the “Company”) (CSE: BNXT / OTC: BNXTF / FSE: BXT) is pleased to...

Continue Reading

Drug Delivery, Press Releases

BIONXT REPORTS UPDATE ON COMMERCIALIZATION OF ROTIGOTINE PATCH FOR TREATMENT OF PARKINSON’S DISEASE   

Feb 13, 2023

VANCOUVER, BC – February 13, 2023 ‐ BioNxt Solutions Inc. (“BioNxt” or the “Company”) (CSE: BNXT / OTC: BNXTF / FSE: BXT) is pleased to...

Continue Reading

Drug Delivery, Press Releases

XPhyto reports excellent Rotigotine in-vitro/ex-vivo results for Parkinson’s disease treatment

Oct 18, 2022

Vancouver, Canada, and Uttenweiler, Germany (October 18, 2022) - XPhyto Therapeutics Corp. (CSE:XPHY / OTC:XPHYF / FSE:4XT) (“XPhyto” or the “Company”) is pleased to report...

Continue Reading

Drug Delivery, Press Releases

XPhyto completes Rotigotine transdermal patch optimization and comparative skin absorption study

Oct 11, 2022

Vancouver, Canada, and Uttenweiler, Germany (October 11, 2022) - XPhyto Therapeutics Corp. (CSE:XPHY / OTC:XPHYF / FSE:4XT) (“XPhyto” or the “Company”) is pleased to provide...

Continue Reading

Diagnostics, Press Releases

XPhyto Signs Letter of Intent for US Manufacturing and Strategic Business Opportunities

Oct 5, 2022

Vancouver, Canada, and Uttenweiler, Germany (October 4, 2022) - XPhyto Therapeutics Corp. (CSE:XPHY / OTC:XPHYF / FSE:4XT) (“XPhyto” or the “Company”) is pleased to report...

Continue Reading

Press Releases, Psychedelics

XPhyto Files Patent Application for Library of Novel Psychedelic Compounds

Sep 20, 2022

Vancouver, Canada, and Uttenweiler, Germany (September 20, 2022) - XPhyto Therapeutics Corp. (CSE:XPHY / OTC:XPHYF / FSE:4XT) (“XPhyto” or the “Company”) is pleased to report...

Continue Reading

Diagnostics, Press Releases

XPhyto Pursues Potential Application of its Oral Dissolvable Biosensor Inflammation Test for Buprenorphine-related Dental Disease

Jul 18, 2022

Vancouver, Canada, and Uttenweiler, Germany (July 18, 2022) - XPhyto Therapeutics Corp. (CSE:XPHY / OTC:XPHYF / FSE:4XT) (“XPhyto” or the “Company”) is pleased to report...

Continue Reading

Press Releases

Prof. Dr. Raimar Loebenberg receives Leadership Award from the Canadian Society for Pharmaceutical Sciences

Jun 27, 2022

Vancouver, Canada, and Uttenweiler, Germany (June 27, 2022) - XPhyto Therapeutics Corp. (CSE:XPHY / OTC:XPHYF / FSE:4XT) (“XPhyto” or the “Company”) is pleased to congratulate...

Continue Reading

Drug Delivery, Press Releases

XPhyto adds pharmaceutical manufacturing expert Dr. Florian A. Sahr to its European team

Jun 8, 2022

Vancouver, Canada, and Uttenweiler, Germany (June 8, 2022) - XPhyto Therapeutics Corp. (CSE:XPHY / OTC:XPHYF / FSE:4XT) (“XPhyto” or the “Company”) is pleased to report...

Continue Reading

Drug Delivery, Press Releases

XPhyto reports product developments on platform-based Rotigotine transdermal patch for Parkinson’s disease

May 9, 2022

Vancouver, Canada, and Uttenweiler, Germany (May 9, 2022) - XPhyto Therapeutics Corp. (CSE:XPHY / OTC:XPHYF / FSE:4XT) (“XPhyto” or the “Company”) is pleased to provide...

Continue Reading